1887

Chapter 16 : Acquired Immunity against Fungi

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Acquired Immunity against Fungi, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817978/9781555812140_Chap16-1.gif /docserver/preview/fulltext/10.1128/9781555817978/9781555812140_Chap16-2.gif

Abstract:

This chapter focuses primarily on four fungi, , , , and , but also considers examples from other fungal pathogens. The primary goal in this chapter is to focus on the general principles involved in the acquired immune response to fungi. Major human fungal pathogens and medical conditions predisposing to invasive disease have been discussed in the chapter. For many bacterial and viral pathogens the importance of acquired immunity is evident from the observation that recovery from symptomatic infection results in long-lasting immunity. Nevertheless, for several fungal pathogens, serological skin reactivity surveys indicate that infections are common but clinical disease is rare, consistent with the development of acquired immunity. Hence, the experience with experimental vaccines against fungi indicates that acquired immunity can be protective against fungi and that both arms of the immune system can be effective depending on the antigen used and the fungal pathogen in question. For many fungal pathogens, the effective tissue response to invasion is granulomatous inflammation. Given that an extensive body of evidence indicates an important role for acquired immunity in host defense against fungal pathogens, it is nevertheless important to consider certain caveats with regard to the studies performed in this field.

Citation: Casadevall A. 2002. Acquired Immunity against Fungi, p 223-234. In Kaufmann S, Sher A, Ahmed R (ed), Immunology of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817978.ch16

Key Concept Ranking

Humoral Immune Response
0.4943501
T Helper Cells
0.4685425
Immune Systems
0.45790353
Tumor Necrosis Factor
0.45513797
0.4943501
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817978.chap16
1. Aguirre, K.,, E. A. Havell,, G. W. Gibson,, and L. L. Johnson. 1995. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect. Immun. 63:17251731.
2. Aguirre, K. M.,, and L. L. Johnson. 1997. A role for B cells in resistance to Cryptococcus neoformans in mice. Infect. Immun. 65:525530.
3. Allen, J. E.,, and R. M. Maizels. 1997. Th1-Th2: reliable paradigm or dangerous dogma. Immunol. Today 18:387392.
4. Allendoerfer, R.,, G. D. Brunner,, and G. S. Deepe, Jr. 1999. Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. J. Immunol. 162:73897396.
5. Allendoerfer, R.,, and G. S. Deepe, Jr. 1998. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J. Immunol. 160: 60726082.
6. Allendoerfer, R.,, D. M. Magee,, G. S. Deepe, Jr.,, and J. R. Graybill. 1993. Transfer of protective immunity in murine histoplasmosis by a CD4+ T-cell clone. Infect. Immun. 61:714718.
7. Ashman, R. B. 1997. Genetic determination of susceptibility and resistance in the pathogenesis of Candida albicans infection. FEMS Immunol. Med. Microbiol. 19:183189.
8. Ashman, R. B.,, A. Fulurija,, and J. M. Papadimitriou. 1999. Both CD4+ and CD8+ lymphocytes reduce the severity of tissue lesions in murine systemic cadidiasis, and CD4+ cells also demonstrate strain-specific immunopathological effects. Microbiology 145:16311640.
9. Ashman, R. B.,, and J. M. Papadimitriou. 1995. Production and function of cytokines in natureal and acquired immunity to Candida albicans infection. Microbiol. Rev. 59:646672.
10. Balish, E.,, F. A. Vazquez-Torres,, J. Jones-Carson,, R. D. Wagner,, and T. Warner. 1996. Importance of β2-microglobulin in murine resistance to mucosal and systemic candidiasis. Infect. Immun. 64:50925097.
11. Balish, E.,, R. D. Wagner,, A. Vazquez-Torres,, C. Pierson,, and T. Warner. 1998. Candidiasis in interferon-gamma knockout (IFNgamma-/ -) mice. J. Infect. Dis. 178:478487.
12. Beaman, L.,, D. Pappagianis,, and E. Benjamini. 1977. Significance of T cells in resistance to experimental murine coccidioidomycosis. Infect. Immun. 17:580585.
13. Bennett, J. E. 1981. Cryptococcal skin test antigen: preparation variables and characterization. Infect. Immun. 32:373380.
14. Calich, V. L.,, C. A. Vaz,, and E. Burger. 1998. Immunity to Paracoccidioides brasiliensis infection. Res. Immunol. 149:407417.
15. Casadevall, A. 1995. Antibody immunity and invasive fungal infections. Infect. Immun. 63:42114218.
16. Casadevall, A.,, A. Cassone,, F. Bistoni,, J. E. Cutler,, W. Magliani,, J. W. Murphy,, L. Polonelli,, and L. Romani. 1998. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med. Mycol. 36:95105.
17. Casadevall, A.,, J. Mukherjee,, S. J. N. Devi,, R. Schneerson,, J. B. Robbins,, and M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65:10861093.
18. Casadevall, A.,, and J. R. Perfect. 1998. Cryptococcus neoformans. American Society for Microbiology. Washington, D.C.
19. Casadevall, A.,, and M. D. Scharff. 1991. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J. Exp. Med. 174: 151160.
20. Cenci, E.,, A. Mencacci,, G. Del Sero,, A. Bacci,, C. Montagnoli,, C. F. d’Ostiani,, P. Mosci,, M. Bachmann,, F. Bistoni,, M. Kopf,, and L. Romani. 1999. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J. Infect. Dis. 180:19571968.
21. Chen, L.-C.,, D. L. Goldman,, T. L. Doering,, L. Pirofski,, and A. Casadevall. 1999. Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect. Immun. 67: 22182224.
22. Cox, R. A.,, and D. M. Magee. 1998. Protective immunity in coccidioidomycosis. Res. Immunol. 148:417428.
23. Currie, B. P.,, and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19:10291033.
24. De Bernardis, F.,, M. Boccanera,, D. Adriani,, E. Spreghini,, G. Santoni,, and A. Cassone. 1997. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65: 33993405.
25. Decken, K.,, G. Kohler,, K. Palmer-Lehmann,, A. Wunderlin,, F. Mattner,, J. Magram,, M. K. Gately,, and G. Alber. 1998. Interleukin- 12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66: 49945000.
26. Deepe, G. S., Jr. 1994. Role of CD8+ T cells in host resistance to systemic infection with Histoplasma capsulatum in mice. J. Immunol. 152:34913500.
27. Deepe, G. S., Jr. 1997. Prospects for the development of fungal vaccines. Clin. Microbiol. Rev. 10:585596.
28. Deepe, G. S., Jr.,, and W. E. Bullock,. 1992. Histoplasmosis. A granulomatous inflammatory response, p. 943958. In J. I. Gallin,, I. M. Goldstein,, and R. Snyderman (ed.), Inflammation: Basic Principles and Clinical Correlates. Raven Press, New York, N.Y.
29. Deepe, G. S., Jr.,, and R. A. Seder. 1998. Molecular and cellular determinants of immunity to Histoplasma capsulatum. Res. Immunol. 149:397406.
30. DeShaw, M.,, and L.-A. Pirofski. 1995. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individuals. Clin. Exp. Immunol. 99:425432.
31. Devi, S. J. N. 1996. Preclinical efficacy of a glucuronoxylomannantetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14:841842.
32. Devi, S. J. N.,, R. Schneerson,, W. Egan,, T. J. Ulrich,, D. Bryla,, J. B. Robbins,, and J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:37003707.
33. Di Salvo, A. F., 2000. Blastomyces dermatitidis, p. 337355. In L. Ajello, and R. J. Hay (ed.), Topley & Wilson’s Microbiology and Microbial Infections. Edward Arnold, London, United Kingdom.
34. Dixon, D. M.,, A. Casadevall,, B. Klein,, L. R. Travassos,, and G. Deepe. 1998. Development of vaccines and their use in the prevention of fungal infections. Med. Mycol. 36(Suppl.):5767.
35. Dixon, D. M.,, M. M. McNeil,, M. L. Cohen,, B. G. Gellin,, and J. R. LaMontagne. 1996. Fungal infections. A growing threat. Public Health Rep. 111:226235.
36. Dromer, F.,, J. Charreire,, A. Contrepois,, C. Carbon,, and P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55:749752.
37. Feldmesser, M.,, and A. Casadevall. 1997. Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans. J. Immunol. 158:790799.
38. Fidel, P. L., Jr.,, and J. D. Sobel. 1998. Protective immunity in experimental Candida vaginitis. Res. Immunol. 149:361373.
39. Fidel, P. L., Jr.,, J. A. Vazquez,, and J. D. Sobel. 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin. Microbiol. Rev. 12: 8096.
40. Fierer, J.,, L. Walls,, L. Eckmann,, T. Yamamoto,, and T. N. Kirkland. 1998. Importance of interleukin-10 in genetic susceptibility of mice to Coccidioides immitis. Infect. Immun. 66: 43974402.
41. Fleuridor, R.,, R. H. Lyles,, and L. Pirofski. 1999. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J. Infect. Dis. 180: 15261535.
42. Fresno, M.,, M. Kopf,, and L. Rivas. 1997. Cytokines and infectious diseases. Immunol. Today 18:5658.
43. Goldman, D.,, S. C. Lee,, and A. Casadevall. 1994. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun. 62:47554761.
44. Goldman, D. L.,, S. C. Lee,, A. J. Mednic,, L. Montell,, and A. Casadevall, 2000. Persistent Cryptococcus neoformans infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness. Infect. Immun. 68:832838.
45. Gomez, F. J.,, R. Allendoerfer,, and G. S. Deepe, Jr. 1995. Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis. Infect. Immun. 63:25872595.
46. Gomez, F. J.,, J. A. Cain,, R. Gibbons,, R. Allendoerfer,, and G. S. Deepe, Jr. 1998. Vbeta4 (+)Tcells promote clearance of infection in murine pulmonary histoplasmosis. J. Clin. Investig. 102: 984995.
47. Grunig, G.,, D. B. Corry,, M. W. Leach,, B. W. Seymour,, V. P. Kurup,, and D. M. Rennick. 1997. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med. 185:10891099.
48. Han, Y.,, and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:27142719.
49. Han, Y.,, and J. E. Cutler. 1997. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J. Infect. Dis. 175:11691175.
50. Han, Y.,, M. H. Riesselman,, and J. E. Cutler, 2000. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 68:16491654.
51. Han, Y.,, M. A. Ulrich,, and J. E. Cutler. 1999. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J. Infect. Dis. 179: 14771484.
52. Hill, J. O. 1992. CD4+ T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J. Exp. Med. 175:16851695.
53. Hoag, K. A.,, M. F. Lipscomb,, A. A. Izzo,, and N. E. Street. 1997. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am. J. Respir. Cell Mol. Biol. 17:733739.
54. Hoag, K. A.,, N. E. Street,, G. B. Huffnagle,, and M. F. Lipscomb. 1995. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am. J. Respir. Cell Mol. Biol. 13:487495.
55. Hobbs, M. M.,, J. R. Perfect,, D. L. Granger,, and D. T. Durack. 1990. Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect. Immun. 58:21152119.
56. Hogan, L. H.,, S. M. Levitz,, and B. S. Klein. 1996. Virulence factors of medically important fungi. Clin. Microbiol. Rev. 9:469488.
57. Huffnagle, G. B. 1996. Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection. Biol. Signals 5:215222.
58. Huffnagle, G. B.,, M. F. Lipscomb,, J. A. Lovchik,, K. A. Hoag,, and N. E. Street. 1994. The role of CD4+ and CD8+T-cells in protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55:3542.
59. Huffnagle, G. B.,, J. L. Yates,, and M. F. Lipscomb. 1991a. T cellmediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect. Immun. 59:14231433.
60. Huffnagle, G. B.,, J. L. Yates,, and M. F. Lipscomb. 1991b. Immunity to pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J. Exp. Med. 173:793800.
61. Hung, C. Y.,, N. M. Ampel,, L. Christian,, K. R. Seshan,, and G. T. Cole, 2000. A major cell surface antigen of Coccidioides immitis which elicits both humoral and cellular immune responses. Infect. Immun. 68:584593.
62. Jiang, C.,, D. M. Magee,, T. N. Quitugua,, and R. A. Cox. 1999. Genetic vaccination against Coccidioides immitis: comparison of vaccine efficacy of recombinant antigen 2 and antigen 2 cDNA. Infect. Immun. 67:630635.
63. Kawakami, K.,, Q. M. Hossain,, T. Zhang,, Y. Koguchi,, Q. Xie,, M. Kurimoto,, and A. Saito. 1999a. Interleukin-4 weakens host resistance to pulmonary and disseminated cryptococcal infection caused by combined treatment with interferon-gamma-inducing cytokines. Cell Immunol. 197:5561.
64. Kawakami, K.,, Y. Koguchi,, M. H. Qureshi,, Y. Kinjo,, S. Yara,, A. Miyazato,, M. Kurimoto,, K. Takeda,, S. Akira,, and A. Saito, 2000. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol. Lett. 186:121126.
65. Kawakami, K.,, M. H. Qureshi,, T. Zhang,, Y. Koguchi,, K. Shibuya,, S. Naoe,, and A. Saito. 1999b. Interferon-gamma (IFN-gamma)- dependent protection and synthesis of chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice infected with Cryptococcus neoformans. Clin. Exp. Immunol. 117:113122.
66. Kirkland, T. N.,, F. Finley,, K. I. Orsborn,, and J. N. Galgiani. 1998a. Evaluation of the proline-rich antigen of Coccidioides immitis as a vaccine candidate in mice. Infect. Immun. 66: 35193522.
67. Kirkland, T. N.,, P. W. Thomas,, F. Finley,, and G. T. Cole. 1998b. Immunogenicity of a 48-kilodalton recombinant T-cell-reactive protein of Coccidioides immitis. Infect. Immun. 66:424431.
68. Klein, B. S.,, P. M. Sondel,, and J. M. Jones. 1992. WI-1, a novel 120-kilodalton surface protein on Blastomyces dermatitidis yeast cells, is a target antigen of cell-mediated immunity in human blastomycosis. Infect. Immun. 60:42914300.
69. Kong, Y.,, and H. B. Levine. 1967. Experimentally induced immunity in the mycoses. Bacteriol. Rev. 31:3553.
70. Kozel, T. R.,, B. C. H. deJong,, M. M. Grinsell,, R. S. MacGill,, and K. K. Wall. 1998a. Characterization of anti-capsular monoclonal antibodies that regulate activation of the complement system by Cryptococcus neoformans. Infect. Immun. 66: 15381546.
71. Kozel, T. R.,, R. S. MacGill,, and K. K. Wall. 1998b. Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule. Infect. Immun. 66: 15471553.
72. Latge, J. P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:310350.
73. Lendvai, N.,, A. Casadevall,, Z. Liang,, D. L. Goldman,, J. Mukherjee,, and L. Zuckier. 1998. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J. Infect. Dis. 177:16471659.
74. Lendvai, N.,, X. Qu,, W. Hsueh,, and A. Casadevall, 2000. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans infected mice. J. Immunol. 164: 43674374.
75. Levitz, S. M.,, H. L. Mathews,, and J. W. Murphy. 1995. Direct antimicrobial activity by T cells. Immunol. Today 16:387391.
76. Lim, T. S.,, and J. W. Murphy. 1980. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect. Immun. 30:511.
77. Lipscomb, M. F.,, G. B. Huffnagle,, J. A. Lovchik,, C. R. Lyons,, A. M. Pollard,, and J. L. Yates. 1993. The role of T lymphocytes in pulmonary microbial defense mechanisms. Arch. Pathol. Lab. Med. 117:12251232.
78. Lovchik, J. A.,, C. R. Lyons,, and M. F. Lipscomb. 1995. A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am. J. Respir. Cell Mol. Biol. 13:116124.
79. Lovchik, J. A.,, J. A. Wilder,, G. B. Huffnagle,, R. Riblet,, C. R. Lyons,, and M. F. Lipscomb. 1999. Ig heavy chain complexlinked genes influence the immune response in a murine cryptococcal infection. J. Immunol. 163:39073913.
80. Magee, D. M.,, and R. A. Cox. 1995. Roles of gamma interferon and interleukin-4 in genetically determined resistance to Coccidioides immitis. Infect. Immun. 63:35143519.
81. Magee, D. M.,, and R. A. Cox. 1996. Interleukin-12 regulation of host defenses against Coccidioides immitis. Infect. Immun. 64: 36093613.
82. Magliani, W.,, S. Conti,, F. De Bernardis,, M. Gerloni,, D. Bertolotti,, P. Mozzoni,, A. Cassone,, and L. Polonelli. 1997. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. 15:155158.
83. Marino, M. W.,, A. Dunn,, D. Grail,, M. Inglese,, Y. Noguchi,, E. Richards,, A. Jungbluth,, H. Wada,, M. Moore,, B. Williamson,, S. Basu,, and L. J. Old. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94:80938098.
84. Matthews, R.,, and J. Burnie,. 1998. Mycoserology, p. 89109. In L. Ajello, and R. J. Hay (ed.), Topley & Wilson’s Microbiology and Microbial Infections, vol. 4. Edward Arnold, London, United Kingdom.
85. Matthews, R. C.,, and J. P. Burnie. 1996. Antibodies and Candida: potential therapeutics. Trends Microbiol. 4:354358.
86. Matthews, R. C.,, J. P. Burnie,, D. Howat,, T. Rowland,, and F. Walton. 1991. Autoantibody to heat shock protein 90 can mediate protection against systemic candidosis. Immunology 74: 2024.
87. Monari, C.,, A. Casadevall,, C. Retini,, F. Baldelli,, F. Bistoni,, and A. Vecchiarelli. 1999. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans. AIDS 13:653660.
88. Monga, D. P.,, R. Kumar,, L. N. Mahapatra,, and A. N. Malaviya. 1979. Experimental cryptococcosis in normal and B-cell deficient mice. Infect. Immun. 26:13.
89. Mukherjee, J.,, G. Nussbaum,, M. D. Scharff,, and A. Casadevall. 1995a. Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J. Exp. Med. 181:405409.
90. Mukherjee, J.,, L. Pirofski,, M. D. Scharff,, and A. Casadevall. 1993. Antibody mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. USA 90:36363640.
91. Mukherjee, J.,, M. D. Scharff,, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:45344541.
92. Mukherjee, S.,, M. Feldmesser,, and A. Casadevall. 1996. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J. Infect. Dis. 173:12221231.
93. Mukherjee, S.,, S. C. Lee,, and A. Casadevall. 1995b. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63: 573579.
94. Murphy, J. W. 1991. Mechanisms of natural resistance to human pathogenic fungi. Annu. Rev. Microbiol. 45:509538.
95. Murphy, J. W. 1998. Protective cell-mediated immunity against Cryptococcus neoformans. Res. Immunol. 149:373386.
96. Nagai, H.,, J. Guo,, H. Choi,, and V. Kurup. 1995. Interferongamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J. Infect. Dis. 172:15541560.
97. Pietrella, D.,, C. Monari,, C. Retini,, B. Palazzetti,, T. R. Kozel,, and A. Vecchiarelli. 1998. Cryptococcus neoformans and Candida albicans regulate CD4 expression on human monocytes. J. Infect. Dis. 178:14641471.
98. Pirofski, L.,, and A. Casadevall. 1996. Antibody immunity to Cryptococcus neoformans: paradigm for antibody immunity to the fungi? Zentbl. Bakteriol. 284:475495.
99. Polonelli, L.,, F. De Bernardis,, M. Boccanera,, M. Gerloni,, G. Morace,, W. Magliani,, C. Chezzi,, and A. Cassone. 1994. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J. Immunol. 152:31753181.
100. Qian, Q.,, and J. E. Cutler. 1997. Gamma interferon is not essential in host defense against disseminated candidiasis in mice. Infect. Immun. 65:17481753.
101. Romagnani, S. 1996. Understanding the role of the Th1/Th2 cells in infection. Trends Microbiol. 4:470473.
102. Romani, L.,, E. Cenci,, A. Mencacci,, R. Spaccapelo,, U. Grohmann,, P. Puccetti,, and F. Bistoni. 1992a. Gamma interferon modifies CD4+ subset expression in murine candidiasis. Infect. Immun. 60:49504952.
103. Romani, L.,, and D. H. Howard. 1995. Mechanisms of resistance to fungal infections. Curr. Opin. Immunol. 7:517523.
104. Romani, L.,, A. Mencacci,, U. Grohmann,, S. Mocci,, P. Mosci,, P. Puccetti,, and F. Bistoni. 1992b. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1- associated immunity in murine candidiasis. J. Exp. Med. 176: 1925.
105. Salvin, S. B. 1959. Current concepts of diagnostic serology and skin hypersensitivity in the mycoses. Am. J. Med. 27:97114.
106. Sanford, J. E.,, D. M. Lupan,, A. M. Schlagetter,, and T. R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58:19191923.
107. Segal, E. 1987. Vaccines against fungal infections. Crit. Rev. Microbiol. 14:229273.
108. Tewari, R.,, L. J. Wheat,, and L. Ajello,. 1998. Agents of histoplasmosis, p. 373393. In L. Ajello, and R. J. Hay (ed.), Topley & Wilson’s Microbiology and Microbial Infections, vol. 4. Edward Arnold, London, United Kingdom.
109. Tripp, C. S.,, K. P. Beckerman,, and E. R. Unanue. 1995. Immune complexes inhibit antimicrobial responses through interleukin- 10 production. J. Clin. Investig. 95:16281694.
110. van Enckevort, F. H.,, M. G. Netea,, A. R. Hermus,, C. G. Sweep,, J. F. Meis,, J. W. Van der Meer,, and B. J. Kullberg. 1999. In creased susceptibility to systemic candidiasis in interleukin-6 deficient mice. Med. Mycol. 37:419426.
111. Vazquez-Torres, A.,, and E. Balish. 1997. Macrophages in resistance to candidiasis. Microbiol. Mol. Biol. Rev. 61:170192.
112. Vazquez-Torres, A.,, J. Jones-Carson,, R. D. Wagner,, T. Warner,, and E. Balish. 1999. Early resistance of interleukin-10 knockout mice to acute systemic candidiasis. Infect. Immun. 67:670674.
113. Vecchiarelli, A.,, and A. Casadevall. 1998. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res. Immunol. 149:321333.
114. Vecchiarelli, A.,, C. Monari,, C. Retini,, D. Pietrella,, B. Palazzetti,, L. Pitzurra,, and A. Casadevall. 1998a. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur. J. Immunol. 28:114121.
115. Vecchiarelli, A.,, C. Retini,, A. Casadevall,, C. Monari,, D. Pietrella,, and T. R. Kozel. 1998b. Involvement of C3a and C5a in Interleukin- 8 secretion by human polymorphonuclear cells in response to capsular polysaccharide material of Cryptococcus neoformans. Infect. Immun. 66:43244330.
116. Vecchiarelli, A.,, C. Retini,, C. Monari,, and A. Casadevall. 1998c. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T cell proliferation. Infect. Immun. 66:12441247.
117. Wagner, R. D.,, A. Vazquez-Torres,, J. Jones-Carson,, T. Warner,, and E. Balish. 1996. B cell knockout mice are resistant to mucosal and systemic candidiasis of endogenous origin but susceptible to experimental systemic candidiasis. J. Infect. Dis. 174: 589597.
118. Wheat, J. 1995. Endemic mycoses in AIDS: a clinical review. Clin. Microbiol. Rev. 8:146159.
119. Wuthrich, M.,, W. L. Chang,, and B. S. Klein. 1998. Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyces dermatitidis. Infect. Immun. 66:54435449.
120. Yang, M. C.,, D. M. Magee,, and R. A. Cox. 1997. Mapping of a Coccidioides immitis-specific epitope that reacts with complement- fixing antibody. Infect. Immun. 65:40684074.
121. Yuan, R.,, A. Casadevall,, J. Oh,, and M. D. Scharff. 1997. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA 94: 24832488.
122. Yuan, R.,, A. Casadevall,, G. Spira,, and M. D. Scharff. 1995. Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to C. neoformans into a protective antibody. J. Immunol. 154:18101816.
123. Yuan, R.,, G. Spira,, J. Oh,, M. Paizi,, A. Casadevall,, and M. D. Scharff. 1998. Isotype switching increases antibody protective efficacy to Cryptococcus neoformans infection in mice. Infect. Immun. 66:10571062.
124. Zhou, P.,, and R. A. Seder. 1998. CD40 ligand is not essential for induction of type 1 cytokine responses or protective immunity after primary or secondary infection with histoplasma capsulatum. J. Exp. Med. 187:13151324.
125. Zhou, P.,, M. C. Sieve,, J. Bennett,, K. J. Kwon-Chung,, R. P. Tewari,, R. T. Gazzinelli,, A. Sher,, and R. A. Seder. 1995. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J. Immunol. 155: 785795.
126. Zhu, Y.,, V. Tryon,, D. M. Magee,, and R. A. Cox. 1997. Identification of a Coccidioides immitis antigen 2 domain that expresses B-cell-reactive epitopes. Infect. Immun. 65:33763380.

Tables

Generic image for table
Table 1

Major human fungal pathogens and medical conditions predisposing to invasive disease

Citation: Casadevall A. 2002. Acquired Immunity against Fungi, p 223-234. In Kaufmann S, Sher A, Ahmed R (ed), Immunology of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817978.ch16
Generic image for table
Table 2

Examples of mouse experiments that indicate the importance of the acquired immune system

Citation: Casadevall A. 2002. Acquired Immunity against Fungi, p 223-234. In Kaufmann S, Sher A, Ahmed R (ed), Immunology of Infectious Diseases. ASM Press, Washington, DC. doi: 10.1128/9781555817978.ch16

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error